2022
Neurogenic orthostatic hypotension after treatment with sorafenib
Wippel C, Deshpande H, Patwa H, Peixoto A. Neurogenic orthostatic hypotension after treatment with sorafenib. BMJ Case Reports 2022, 15: e247140. PMID: 36549761, PMCID: PMC9791444, DOI: 10.1136/bcr-2021-247140.Peer-Reviewed Original ResearchConceptsOrthostatic hypotensionVascular endothelial growth factor inhibitorsLower extremity weaknessNeurogenic orthostatic hypotensionPalpable abdominal massGrowth factor inhibitorsHistory of fatigueAppropriate chronotropic responseSupine hypertensionAbdominal painAutonomic testingExtremity weaknessAbdominal massSodium intakeChronotropic responseFactor inhibitorsCompression stockingsDesmoid tumorsLiberal fluidsSympathetic responseHypotensionTumor growthSorafenibGradual improvementTreatment
2018
Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
Gounder M, Mahoney M, Van Tine B, Ravi V, Attia S, Deshpande H, Gupta A, Milhem M, Conry R, Movva S, Pishvaian M, Crawford J, Sabagh T, Maki R, Tap W, Lefkowitz R, Agaram N, Wright J, Dueck A, Schwartz G. Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105). Journal Of Clinical Oncology 2018, 36: 11500-11500. DOI: 10.1200/jco.2018.36.15_suppl.11500.Peer-Reviewed Original Research